Refining patient selection for neoadjuvant chemotherapy before radical cystectomy

Area of Science:

• Urology
• Oncology
• Cancer Research

Background:

• Muscle invasive bladder cancer (MIBC) requires careful treatment stratification.
• Radical cystectomy is a primary treatment, but neoadjuvant chemotherapy can improve outcomes for high-risk patients.

Purpose of the Study:

• To evaluate the survival of MIBC patients undergoing radical cystectomy without neoadjuvant chemotherapy.
• To validate clinical tools for identifying low-risk patients suitable for surgery alone and high-risk patients who would benefit from neoadjuvant chemotherapy.

Main Methods:

• Retrospective analysis of 98 high-risk and 199 low-risk MIBC patients undergoing radical cystectomy (2000-2010).
• High-risk criteria included hydroureteronephrosis, cT3b-T4a disease, lymphovascular invasion, micropapillary, or neuroendocrine features.
• Survival outcomes (disease-specific, progression-free, overall) and pathological upstaging rates were assessed. Findings were validated in an independent cohort.

Main Results:

• High-risk patients had significantly decreased 5-year overall (47.0% vs 64.8%), disease-specific (64.3% vs 83.5%), and progression-free (62.0% vs 84.1%) survival compared to low-risk patients (p <0.001).
• These survival differences were confirmed in the validation cohort.
• 49.2% of low-risk patients experienced pathological upstaging.

Conclusions:

• A 5-year disease-specific survival exceeding 80% in low-risk MIBC patients supports distinguishing between high-risk and low-risk disease.
• High-risk features identify patients with poor prognosis likely to benefit from neoadjuvant chemotherapy.
• Low-risk patients may undergo upfront radical cystectomy, avoiding chemotherapy toxicity while maintaining good survival expectations.